Maximillian Von Strandtmann

This inventor holds 5 USPTO granted patents. Top assignee: Warner-Lambert Company. Active years: 1977-1980.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Maximillian Von Strandtmann. Retrieved from https://idiyas.com/inventor/maximillian-von-strandtmann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5

% Patents Active = 100.0

Average Co-Inventor Count = 3.3

ph-index = 1

Forward Citations = 7(Granted Patents)

Location History:

Rockaway, NJ (US) (1977 - 1979)
New Castle, DE (US) (1978 - 1980)

Company Filing History:

5 out of 2,538

Warner-Lambert Company

patents

Years Active: 1977-1980

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 4191825 - Diacyloxyacids derived from acid S, an antibiotic produced by Polyangium (1980-03-04),

2. 4138550 - Diacyloxyacids derived from acid S, an antibiotic produced by Polyangium (1979-02-06),

3. 4127669 - [(4-Oxo-4H-1-benzopyran-3-yl)oxy] acetic acids and derivatives (1978-11-28),

4. 4098998 - Aldehyde, oxime and phenylhydrazone derivatives of acid S, an antibiotic (1978-07-04),

5. 4056532 - Alpha-aryl-2-pyridineethanol 1-oxides and (1977-11-01),

Title: Maximillian Von Strandtmann: Innovator in Antibiotic Development

Introduction

Maximillian Von Strandtmann is a notable inventor based in Rockaway, NJ, with a strong focus on the field of antibiotics and antifungal agents. With a record of five patents, his contributions to pharmaceutical innovations have garnered attention and respect within the industry.

Latest Patents

Among his significant inventions are diacyloxyacids derived from the antibiotic substance designated as acid S, produced by Polyangium cellulosum var. fulvum (ATCC No. 25532). This innovative work describes processes for their production and highlights their potential as effective antifungal and antibacterial agents. His latest patent contributes significantly to the ongoing search for novel antibiotic solutions.

Career Highlights

Maximillian currently works with the Warner-Lambert Company, where he applies his expertise in the development of pharmaceutical products. His innovative spirit and dedication to research allow him to remain at the forefront of antibiotic development.

Collaborations

Collaboration has been a key element in Maximillian's career. He has worked alongside esteemed colleagues such as David T. Connor and Samuel M. Ringel, whose combined efforts have further enhanced their contributions to the field of medicinal chemistry.

Conclusion

Maximillian Von Strandtmann continues to push the boundaries of innovation within antibiotic research. As he develops new compounds like diacyloxyacids, his work promises to improve treatment options for infectious diseases, marking significant progress in the quest for effective medicinal solutions.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]